Celltrion Accelerates European Expansion with 'Remsima'

Celltrion Healthcare's 'Remsima (generic name infliximab)' is solidifying its position as the market share leader by continuously winning bids for infliximab-based drugs in major European countries, outperforming competing products.

Remsima SC Model
Photo by Lee Chunhee

Celltrion Healthcare announced on the 18th that it recently succeeded in winning the AGEPS bid held in France, one of the five major EU countries (EU5). Through this, Remsima will be supplied for three years from this month until 2026 to APHP (Assistance Publique - H?pitaux de Paris), a consortium of university hospitals in Paris and the ?le-de-France region. According to IQVIA, a pharmaceutical market research firm, Remsima recorded a prescription performance that overwhelmingly surpassed both original and competing products with a 59% market share in France as of the second quarter. With the success in the AGEPS bid, expectations are high that Remsima's influence in France will be further strengthened.

In Italy, another EU5 country, bidding successes continue. Remsima won the infliximab bid in the Umbria region of central Italy. In particular, another autoimmune disease treatment, 'Yuflyma (generic name adalimumab),' succeeded in government bids in five Italian provinces in the third quarter of this year alone, demonstrating that the local subsidiary is steadily expanding the market share of the entire autoimmune disease product portfolio.

Celltrion Healthcare cited the product competitiveness of Remsima, which recently celebrated its 10th anniversary since its launch in Europe, as the driving force behind its sustained bidding success over a long period. As an infliximab product with over 20 years of proven efficacy and safety in medical practice, the introduction of 'Remsima SC,' the world's only subcutaneous (SC) formulation of infliximab, has particularly increased the preference of European healthcare professionals and patients for the Remsima product line.

Additionally, the company noted that the strength of the dual formulation?switching from other infliximab products to Remsima followed by maintenance therapy with Remsima SC?has demonstrated competitiveness, leading to a simultaneous increase in the market shares of both products. Accordingly, as Remsima SC prescriptions expand across Europe, it is expected that Remsima prescriptions will continue to grow as well.

The company also projected that once the ongoing merger with Celltrion is completed, it will present a new growth opportunity to drive the expansion of Remsima sales. The merger is expected to improve cost ratios, increase profits for the merged company, and enable the establishment of a more differentiated pricing strategy, allowing proactive participation in more bidding competitions across Europe and thereby expanding Remsima's market share.

Celltrion's autoimmune disease treatment 'Remsima (generic name: infliximab)'
[Photo by Celltrion Healthcare]

A Celltrion Healthcare official said, "Despite Remsima representing the company for a long time and 10 years having passed since its launch in Europe, the reason it continues to expand its achievements is the strong trust of local healthcare professionals and patients in Remsima's unique product competitiveness." He added, "Based on the sales synergy with Remsima SC, the world's only subcutaneous infliximab formulation, and the improved cost ratio expected after the merger completion, we will do our best to ensure that the Remsima product line continues to be delivered to patients as a representative treatment for autoimmune diseases for an even longer period."

This content was produced with the assistance of AI translation services.